Background: 5-aminosalicylic acid (5-ASA) is the first-line therapy for ulcerative colitis
| INTRODUCTION
Mesalazine or 5-aminosalicylic acid (5-ASA) is the first line therapy for patients with ulcerative colitis (UC), and is effective both for inducing and maintaining remission.
1,2 5-ASA is proposed to act through numerous mechanisms, including inhibition of pro-inflammatory mediators such as leukotriens, prostaglandin, interleukin-1, Nuclear factor-κB (NF-κB) and tumour necrosis factor alpha (TNFα), as well as a peroxisome proliferator-activated receptor gamma (PPAR-γ) receptor agonist (reviewed by Lichtenstein and Kamm 3 ).
5-ASA exerts its effect in the intestinal mucosa, and mucosal 5-ASA concentrations are inversely correlated to disease activity. [4] [5] [6] [7] It is therefore important to identify and understand the determinants of mucosal 5-ASA concentration. In the intestinal mucosa, 5-ASA is acetylated to its inactive metabolite N-acetyl-5-ASA (Ac-5-ASA), mainly by the enzyme N-acetyl-transferase 1 (NAT1), and to a small degree by N-acetyl-transferase 2 (NAT2). 8, 9 Orally administered unbound 5-ASA is absorbed and inactivated in the small intestinal mucosa and in the liver, thus only small amounts 5-ASA will reach the colonic mucosa. 3, 10 Therefore, several pharmaceutical delivery systems have been developed to transport orally administered 5-ASA to the colon. In a time-dependent formulation (Pentasa, Ferring Pharmaceuticals, Saint-Prex, Switzerland), 5-ASA is coated with a semipermeable membrane of ethyl cellulose, providing a pH-independent release of approximately 35% of its content in the small bowel, 25% in the colon, while the last 40% eliminates in the faeces. 11 In a pH-dependent delivery system (Asacol, Tillots Pharma AG, Rheinfelden, Switzerland), 5-ASA is coated with Eudragit S which dissolves at a pH >7, 12 normally occurring in the terminal ileum and caecum.
The Multi Matrix System (Mezavant, Shire Pharmaceutical Contracts
Ltd, in partnership with Cosmo SpA, Milan, Italy) consists of hydrophilic and lipophilic excipients, covered by a pH-dependent coating dissolving at pH 7, causing slow diffusion of the drug into the gut lumen. 3 For both Asacol and Mezavant absorption in the ileum is estimated to be around 20%. 13, 14 Faecal elimination for Asacol and Pentasa has been found to be similar. 12 After oral administration of 5-ASA, mucosal concentrations are highest in the proximal colon segments and lowest in the rectum for the previously examined preparations. 7, 15, 16 Higher concentrations in the rectum and left hemicolon have been achieved by combining oral and rectal 5-ASA formulations. 16, 17 However, rectal administration may be inconvenient and adherence to treatment over time is low.
As 65%-85% of patients with UC have rectosigmoid and left-sided involvement at the time of diagnosis, 18, 19 it seems essential to assure optimal concentrations of 5-ASA in these bowel segments.
Although previous studies suggest that Asacol yields higher mucosal 5-ASA concentrations than Pentasa, 4,15 the different 5-ASA formulations are by many considered clinically equally efficient. 2 Studies comparing mucosal 5-ASA concentrations of the more recently marketed Mezavant with other 5-ASA formulations, have to the best of our knowledge, not been published.
Patients with UC have an altered gut microbiome, commonly called dysbiosis. Microbiome alterations in UC are characterised by reduced alpha-diversity [20] [21] [22] [23] combined with increases in the Proteobacteria phylum 22, 24, 25 and decreases in the Firmicutes phylum. 21, 25, 26 At genus level, Roseburia is reported to be decreased and Haemophilus increased. 27 The effect of selected antibiotics, probiotics and faecal microbiota transplantation 28 supports that dysbiosis is a part of the pathogenesis in UC. 5-ASA has previously also been reported to affect intestinal bacteria, by inhibiting growth of anaerobic strains, reducing bacterial invasiveness and total faecal bacterial abundance, [29] [30] [31] as well as reducing bacterial adherent biofilm thickness and Escherichia and Shigella abundances in patients with inflammatory bowel disease (IBD). 21, 32 Results from a recent study also suggest that 5-ASA acts as a polyP-kinase inhibitor, thereby decreasing some bacteria's ability to colonise and increase their susceptibility to oxidative stress. 33 In the current study, we aimed to measure and compare mucosal 5-ASA concentrations in the left hemicolon and rectum in patients with quiescent UC using different oral 5-ASA formulations (Mezavant, Asacol or Pentasa). We also aimed to explore underlying mechanisms which could explain variations in mucosal 5-ASA concentration as well as exploring the interrelation between 5-ASA mucosal concentration and bacterial composition.
| MATERIALS AND METHODS

| Study population
Patients were recruited from the Department of Gastroenterology 
| Evaluation of disease characteristics and inflammation
Demographic and clinical characteristics were recorded. Disease activity was assessed by clinical and endoscopic Mayo score, 34 Geboes histological score 35 | 1303 microbiome were imported into the DESeq2 R package to estimate which OTUs that significantly correlated with log-transformed mucosal 5-ASA concentrations. 38 Significant OTUs were identified using a regression model in DESeq2 using default options and P-values were estimated using a Wald test and adjusted for multiple testing by
Benjamini Hochberg false discovery rate correction.
T A B L E 1 Demographic and clinical characteristics of patients with ulcerative colitis using three different oral 5-aminosalicylic acid (5-ASA) formulations
Number of patients, n 18 14 10 -
Age at diagnosis (y), mean ( Percentage of patients on monotherapy with oral 5-ASA and no co-medication. For patients using co-medication, the following drugs were used: amiloride/hydrochlorothiazide (n = 1), lisinopril/hydrochlorothiazide (n = 1), losartan/ hydrochlorothiazide(n = 1), calcium and cholecalciferol (n = 3), zoledronate (n = 1), alendronate (n = 2), pantoprazole (n = 1), esomeprazole (n = 1), drospirenone/ethinylestradiol (n = 1), estradiol/norethindrone acetate (n = 1), ethinylestradiol/levonorgestrel (n = 1), venlafaxine (n = 2), levothyroxine (n = 2), tiotropium bromide (n = 1), simvastatin (n = 1), cetirizine (n = 1), paracetamol (n = 1), zolmitriptan (n = 1), sumatriptan (n = 1), desoximetasone crème 2.5 mg/g (n = 1), terbinafine (n = 1). 
| RESULTS
| Patient characteristics
Demographic and clinical characteristics are presented in Table 1 .
Overall the three 5-ASA formulation groups were similar. There were no significant differences in total Mayo score (P = 0.055) or proportion of patients in deep remission (P = 0.750). However, the Asacol group had higher leukocyte concentrations (P = 0.036), and the Mezavant group had higher endoscopic Mayo scores (P = 0.01) and fewer patients in endoscopic remission (P = 0.021). All Pentasa patients were classified to be in endoscopic remission, while 12 (67%) Mezavant patients and 13 (93%) Asacol patients were in endoscopic remission (P = 0.021). The proportion of patients in histological remission was, however, lowest in the Pentasa group, n = 7 (70%). The overall test for difference in adjusted mean 5-ASA concentration (averaged over location) between the three 5-ASA formulation groups (Table 2) (Table 3 ).
| Mucosal 5-ASA concentration was positively associated to abundance of numerous beneficial bacteria
Mucosal 5-ASA concentration was significantly associated to the mucosal bacterial abundance on all taxonomic levels (Table 4) , whereas the association to bacterial abundance in faecal samples was weaker (Table 5 ). Mucosal 5-ASA concentration and alpha-diversity was positively associated in mucosal biopsies (P = 4.7 × 10 In faeces, two bacterial genera were associated with 5-ASA mucosal concentration; Prevotella (P = 7.2 × 10 −5 ) and Sutterella (P = 0.03), both genera were negatively associated with 5-ASA concentrations (Table 5) .
T A B L E 2 Mucosal concentrations (ng/mg) of 5-aminosalicylic acid (5-ASA) and acetylated 5-ASA (Ac-5-ASA) in the left hemicolon and rectum in patients with ulcerative colitis using three different oral 5-ASA formulations Bacteria within each taxonomic level are listed by increasing P-values. P = adjusted P-value, B = regression coefficient. Red text = increased abundance (positive association), blue = decreased abundance (negative association).
T A B L E 5 Faecal bacteria abundances significantly associated with 5-aminosalicylic acid (5-ASA) concentration on different taxonomic levels (regression analysis) Bacteria within each taxonomic level are listed by increasing P-values. P = adjusted P-value, B = regression coefficient, Blue text = decreased abundance (negative association). (Table 6) .
Thirty-one patients (73.8%) had a slow acetylator NAT2 phenotype (Table S3) . Patients with NAT1 slow acetylators status had significantly higher 5-ASA serum concentrations (P = 0.044) than patients with NAT1 rapid acetylator status. There was no significant association between serum 5-ASA concentration and NAT2 genotype (P = 0.708). Mucosal 5-ASA concentration was not significantly associated with neither NAT1 (P = 0.276) nor NAT2 (P = 0.488) genotype.
| DISCUSSION
This is the first study to measure mucosal 5-ASA concentration in UC patients using different oral 5-ASA formulations, and correlating it to NAT genotype and bacterial microbiota. Concurring with previous findings, our patients had declining concentrations of 5-ASA towards the rectum. 16 A novel finding was that patients using Mezavant had higher overall mucosal 5-ASA concentrations, compared to patients using Pentasa, while there was no significant difference between patients using Mezavant and Asacol. All patients used high doses of 5-ASA, however the manufacturers' maximal recommended dose of Pentasa (4.0 g) is 17% lower than of Mezavant (4.8 g) and Asacol (4.8 g), but this could only explain a minor proportion of the observed differences. The large inter-individual variation in concentration was consistent with previous reports, 4-7 whereas the intra-individual variation between bowel segments was small. Factors such as colonic transit time, intraluminal pH and disease pattern may affect dissolution and uptake of 5-ASA in the colon 39 and could explain some of the inter-individual variation in 5-ASA concentration reported in the present and previous studies. 4, 15, 16 The mucosal Ac-5-ASA concentration reflects the amount of 5-ASA metabolised by NAT1 in the colonic mucosa. There were no significant differences Table 4 belong, may protect against UC as they are increased in healthy twins discordant for UC. 22 One genus, Cloacibacterium, was found to be negatively associated to mucosal 5-ASA concentration, recently this genus has been reported to be more abundant in inflamed vs. non-inflamed tissue of UC patients. 23 Although 16S rRNA sequencing may not be the preferred method for analysing bacteria on species level, the mucosal 5-ASA concentration was positively associated with the mucosal abundance of F. prausnitzii. Faecalibacterium prausnitzii is found to be depleted in UC patients and inversely correlated with disease activity, whereas increased abundance is associated with long-term remission. 44, 47 The mucosal 5-ASA concentration was not associated with alterations in the faecal bacteriome to the same extent as the mucosal bacteriome. The faecal bacterial diversity, and bacterial abundance on phylum level, were not associated with mucosal 5-ASA concentrations. However, abundances of the Betaproteobacteria class and
Burkholderiales order in faeces were negatively associated to mucosal 5-ASA concentration, the former association was also found in the mucosa and is presumed favourable in UC. 24, 42 5-ASA concentration have previously been found to be inversely correlated to disease activity index scores, 5,7 endoscopic and histologic remission 4, 6 in UC patients with mild to moderate disease activity. In the present study, patients had low disease activity, and in contrast to previous findings, the 5-ASA concentration was not significantly associated with the combined parameters of disease activity. Such associations may not be evident within a relatively homogenous patient group with low disease activity. In fact, there was a trend towards higher mucosal 5-ASA concentrations in patients with higher endoscopic scores and it is unlikely that the microbiome features associated with mucosal 5-ASA concentration were confounded by the degree of inflammation. NAT1 and NAT2
genotypes have previously not been found to influence treatment efficacy, 48 but studies correlating NAT genotypes to 5-ASA mucosal concentrations have previously not been published. We found no correlation between NAT genotypes and mucosal 5-ASA concentration, thus NAT1 genotype cannot explain the large inter-individual variations in mucosal 5-ASA concentrations in our study. Interestingly we found that patients with the NAT1 slow acetylator genotype had significantly higher serum 5-ASA concentrations compared to patients with NAT1 rapid acetylator genotype, which could theoretically influence the risk of concentration dependent systemic adverse effects.
| CONCLUSION S
Patients using Mezavant had significantly higher mucosal 5-ASA concentrations than patients using Pentasa. Our results suggest that 5-ASA increases bacterial diversity, favours numerous beneficial bacteria and inhibits disadvantageous bacteria in UC patients. In conclusion, our novel findings indicate that 5-ASA may have positive effects on the mucosal microbiome and could amend dysbiosis in UC patients.
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